BCBao Chai

Bao Chai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bao Chai has a total of 52 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Repurposing Azeliragon as a novel antibacterial agent against methicillin-resistant Staphylococcus aureus via combined membrane phospholipids and cell wall targeting

    by Junhua Ma, Yuqing Xia, Jintuan Lin, Chengchun Chen, Qingyin Meng, Zhijian Yu, Lili Ouyang, Bao Chai, Bing Bai, TieYing Hou, et al.

    Methicillin-resistant Staphylococcus aureus (MRSA) poses a persistent clinical threat due to limited therapeutic options and the rapid emergence of resistance. Azeliragon, an orally bioavailable Receptor for Advanced Glycation End-products (RAGE) inhibitor previously tested in human trials, was identified as a potential antibacterial agent against MRSA through high-throughput screening. It exhibited potent antibacterial activity against clinical S. aureus isolates (MIC50 = 6.25 μM/3.3 μg/mL) and significantly inhibited biofilm formation. Metabolomics and proteomics suggested perturbation of lipid pathways and potential interaction with MurA. Target validation using Drug Affinity Responsive Target Stability (DARTS), Determination of biomolecular affinity by bio-layer interferometry (BLI), Limited proteolysisemass spectrometry (LiP-MS), and site-directed mutagenesis provided biochemical evidence supporting MurA as an intracellular target. Whole Genome Sequencing of resistant derivatives revealed Single Nucleotide Polymorphisms (SNPs) in cell-wall and fatty-acid efflux regulators including yycH, farE/farR, consistent with membrane and cell-wall perturbation. In a murine wound model Azeliragon reduced local bacterial burden and accelerated healing to levels comparable with vancomycin. Azeliragon is a repurposable antibacterial agent that perturbs membrane phospholipid homeostasis and engages MurA-dependent peptidoglycan synthesis. These findings support further preclinical development of Azeliragon or optimized derivatives as potential therapeutics against MRSA and other gram-positive pathogens.

  • IL-6–Mediated Neurogenic Inflammation Regulated by the Dorsal Root Ganglion Macrophages Exacerbates Imiquimod-Induced Psoriasis-Like Skin Lesions in Mice

    by Jian Jiang, Yinlian Zhang, Yi Kong, Qingtian Luo, Yunqing Hou, Li Li, Suwen Liu, Qingxiao Tao, Shiying Lin, Jingyu Zhang, et al.


  • Open Access

    A novel lncRNA YIL163C enhances genomic stability and antifungal resistance via the DNA damage response in Saccharomyces cerevisiae

    by Xueting Wang, Xuemei Li, Duoyun Li, Yiying Zhang, Bing Bai, Bao Chai, Zewen Wen

    Introduction: Long non-coding RNAs (lncRNAs) are increasingly recognized as key regulators in cellular processes, including the DNA damage response (DDR). In Saccharomyces cerevisiae, DDR is critical for maintaining genomic integrity under stress, mediated by proteins like Mec1 and Rad53. However, the involvement of lncRNAs in DDR pathways, remains largely unexplored. This study investigates the function of a novel lncRNA, YIL163C, in promoting cell survival and genomic stability under DNA damage conditions.Methods: Genetic suppressor screening was employed to assess the role of YIL163C in rescuing lethality in mec1Δ sml1Δ and rad53Δ sml1Δ exposed to DNA damage. Proteomic and phosphoproteomic analyses were conducted to evaluate changes in protein abundance and phosphorylation states. The impact of YIL163C on DDR and antifungal drug tolerance, specifically to 5-fluorocytosine, was also examined.Results: Overexpression of YIL163C was found to rescue lethality in mec1Δ sml1Δ and rad53Δ sml1Δ under DNA damage conditions. Proteomic analyses revealed that YIL163C modulates pathways related to DNA replication, ER stress response, and ribosome biogenesis, enhancing cellular resilience to HU-induced stress. Additionally, YIL163C reduced sensitivity to 5-fluorocytosine, indicating a role in antifungal drug tolerance. Phosphoproteomic data suggested YIL163C influences phosphorylation states, potentially acting downstream of the Mec1-Rad53 signaling pathway.Conclusion: This study provides new insights into the regulatory mechanisms of lncRNAs in DDR, with broader implications for antifungal therapy and genomic stability research, emphasizing the role of lncRNAs in stress responses beyond traditional protein-centric mechanisms.


  • AIEgens-enhanced rapid sensitive immunofluorescent assay for SARS-CoV-2 with digital microfluidics

    by Yuping Zeng, Xiangyu Gan, Zhourui Xu, Xiaoxiang Hu, Chenxuan Hu, Hanbin Ma, Hangjia Tu, Bao Chai, Chengbin Yang, Siyi Hu, et al.


  • Open Access

    Evidence for the Clinical Association between Demodex and Rosacea: A Review

    by Fen Wei, Li Li, Yi Kong, Xiaofeng Yan, Kevin J. Varghese, Song Zhang, Jian Jiang, Bao Chai, Hongxiang Chen

    Background: Rosacea is a chronic inflammatory dermatological condition in humans, and its pathogenesis remains unclear. However, the development of rosacea is suspected to be related to Demodex, a microscopic commensal organism that resides in or near hair follicles and sebaceous glands. Although Demodex is known to be a host-specific, obligate commensal organism, it is currently difficult to be cultured in vitro to parasitize and infect other animal hosts. Therefore, direct evidence for a pathogenic role of Demodex in rosacea is currently lacking. Summary: As circumstantial evidence, non-invasive skin-detecting techniques have shown abnormally elevated numbers of Demodex in rosacea patients. Increased cytokine levels such as IL-10, IL-8, and IL-12p70 have been observed in human sebocytes following the Demodex challenge, and acaricides have been found to be effective in rosacea therapy, all point to a close relationship between Demodex and rosacea. Based on these findings, we conducted a comprehensive literature review to summarize the current state of knowledge, research insights, and clinical treatment recommendations for Demodex-associated rosacea, with the ultimate goal of improving patient outcomes.


  • Advanced design and applications of digital microfluidics in biomedical fields: An update of recent progress

    by Chengbin Yang, Xiangyu Gan, Yuping Zeng, Zhourui Xu, Longqian Xu, Chenxuan Hu, Hanbin Ma, Bao Chai, Siyi Hu, Yujuan Chai